66th ASH Annual Meeting: 627. Aggressive Lymphomas: Pharmacologic Therapies: New R-CHOP Combinations for Treatment Naïve DLBCL

Symposia: Aggressive Lymphomas: Pharmacologic Therapies Oral and Poster Abstracts
Oral

Research, Clinical trials, Adult, Combination therapy, Non-Hodgkin lymphoma, Lymphomas, Bispecific Antibody Therapy, Assays, Drug development, Clinical Research, B Cell lymphoma, Diseases, Real-world evidence, Biological therapies, Treatment Considerations, Aggressive lymphoma, Immunotherapy, Lymphoid Malignancies, Technology and Procedures, Human, Study Population, Measurable Residual Disease , Imaging, Molecular testing

Ballroom 20AB (San Diego Convention Center)

Moderators:

Eliza A. Hawkes, MD, Austin Health and Matthew Matasar, MD, MS, Rutgers

Disclosures:

Hawkes: AstraZeneca: Membership on an entity's Board of Directors or advisory committees, Other: Trial Steering Committee, Research Funding, Speakers Bureau; Merck KGaA: Research Funding; Gilead: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Merck Sharpe and Dohme: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sobi: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees, Research Funding; Antengene: Membership on an entity's Board of Directors or advisory committees; Bristol Myer Squibb: Membership on an entity's Board of Directors or advisory committees, Other: Trial Steering Committee, Research Funding; Novartis: Membership on an entity's Board of Directors or advisory committees; Regeneron Pharmaceuticals, Inc.: Membership on an entity's Board of Directors or advisory committees, Other: Trial Steering Committee, Speakers Bureau. Matasar: Bayer: Consultancy, Honoraria, Research Funding; Merck: Current equity holder in publicly-traded company; Allogene: Membership on an entity's Board of Directors or advisory committees; Genmab: Membership on an entity's Board of Directors or advisory committees; GM Biosciences: Consultancy, Research Funding; Genentech: Consultancy, Honoraria, Research Funding; Pharmacyclics: Consultancy, Honoraria, Research Funding; Seattle Genetics: Consultancy, Honoraria, Research Funding; Roche: Consultancy, Honoraria, Research Funding; Johnson & Johnson: Consultancy, Honoraria, Research Funding; Immunovaccine Technologies: Research Funding; ADC Therapeutics: Honoraria; AstraZeneca: Honoraria; BMS/Celgene: Honoraria; Kite: Honoraria; Epizyme: Honoraria; IMV Therapeutics: Honoraria; Pfizer: Honoraria; Takeda: Honoraria; Regeneron Pharmaceuticals, Inc.: Honoraria.

Presentations in this session focus on novel therapies combined with standard immunochemotherapy such as RCHOP or PolaR-CHP in newly diagnosed Diffuse Large B cell Lymphoma

12:00 PM

577

Final Analysis of the Safety and Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit Lymphoma

Catherine S. Diefenbach, MD¹, Andrew D. Zelenetz²^*, Charles Herbaux, MD, PhD³^*, Monica Tani⁴^*, Roch Houot, MD, PhD⁵^*, Mariana Bastos-Oreiro⁶^*, Hervé Tilly⁷, Thomas Gastinne, MD⁸^*, Catherine Thieblemont, MD⁹, Wilfred Leung¹⁰^*, Katerina Hatzi¹⁰^*, Murali Kesavan¹¹^*, Simona Barlera¹²^*, Michelle Boyer¹⁰^* and Franck Morschhauser, MD, PhD¹³

¹Perlmutter Cancer Center, NYU Langone Health, New York, NY
²Memorial Sloan Kettering Cancer Center, New York, NY
³Centre Hospitalier Universitaire de Montpellier, Montpellier, France
⁴Ospedale Santa Maria delle Croci, Ravenna, Italy
⁵Centre Hospitalier Universitaire de Rennes - Hôpital Pontchaillou, Rennes, France
⁶Hematology Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
⁷Department of Hematology, Centre Henri Becquerel, Rouen, France
⁸Centre Hospitalier Universitaire de Nantes, Nantes, France
⁹Hospital Saint-Louis, Paris, France
¹⁰Genentech, Inc., South San Francisco, CA
¹¹F. Hoffmann-La Roche Ltd, London, United Kingdom
¹²Parexel International, Milan, Italy
¹³Centre Hospitalier Régional Universitaire de Lille, Lille, France

12:15 PM

578

Waveline-007: Dose Escalation and Confirmation, and Efficacy Expansion Trial of Zilovertamab Vedotin in Combination with Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab in Patients with Diffuse Large B Cell Lymphoma

Muhit Ozcan, MD¹, Eva Gonzalez Barca²^*, Tae Min Kim, MD, PhD³^*, Ewa Paszkiewicz-Kozik⁴^*, Jan M. Zaucha⁵^*, Stefan Hohaus, MD⁶^*, Marco Ladetto, MD⁷, Caterina Patti⁸^*, Sebastian Giebel, MD, PhD⁹^*, Tadeusz Robak¹⁰^*, Ömür Gökmen Sevindik¹¹^*, Yulia Volchek¹²^*, Benedetta Puccini, MD¹³^*, Guillermo Rodríguez Garcia¹⁴^*, Raul Cordoba, MD, PhD¹⁵, Okan Seyran¹⁶^*, Siruo Wang¹⁷^*, L. Puja Patel¹⁷^*, Rushdia Yusuf¹⁷ and David Lavie¹⁸^*

¹Hematology Department, Ankara University School of Medicine, Cankaya-Ankara, Turkey
²Clinical Hematology Department, Institut Català d’Oncologia-Hospitalet, IDIBELL, Barcelona, Spain
³Seoul National University Hospital, Seoul, Korea, Republic of (South)
⁴Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland
⁵Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk, Poland
⁶Unit of Extramedullary Lymphoproliferative Diseases, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
⁷Department of Translational Medicine, Università del Piemonte Orientale ed SCDU Ematologia AOU SS Antonio e Biagio e Cesare Arrigo, Alessandria, Piedmont, Italy
⁸Onco-Hematology Unit, Azienda Ospedaliera Riunita Villa Sofia-Vincenzo Cervello, Palermo, Italy
⁹Department of Bone Marrow Transplantation and Onco-Hematology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland
¹⁰Department of Hematology, Medical University of Lodz, Lodz, Poland
¹¹Department of Hematology, Medipol University Faculty of Medicine, Istanbul, Turkey
¹²Sheba Medical Center, Ramat Gan, Israel
¹³Unit of Hematology, Careggi University-Hospital, Florence, Italy
¹⁴Hospital Universitario Virgen del Rocío, Seville, Spain
¹⁵Health Research Institute, Fundación Jimenez Diaz University Hospital, Madrid, Spain
¹⁶Trakya University Balkan Hospital, Istanbul, Turkey
¹⁷Merck & Co., Inc., Rahway, NJ
¹⁸Hadassah Medical Center, Jerusalem, Israel

12:30 PM

579

Golcadomide (GOLCA) Plus R-CHOP Has High Minimal Residual Disease (MRD) Negativity across High-Risk, Untreated Aggressive B-Cell Lymphoma (a-BCL)

Arnaud Amzallag, PhD¹^*, Tara Basavanhally, MSc²^*, Jason R. Westin, MD³, Marc Hoffmann, MD⁴, Theodoros P. Vassilakopoulos, MD, PhD⁵^*, Javier Munoz, MD⁶^*, Grzegorz S. Nowakowski, MD⁷, Floriane Boucaud, PhD²^*, Matt Stokes, PhD⁸^*, Akshay Sudhindra, MD², Anita K. Gandhi, PhD⁹ and Mark Kaplan, PhD⁸^*

¹Bristol Myers Squibb, Cambridge, MA
²Bristol Myers Squibb, Princeton, NJ
³MD Anderson Cancer Center, Houston, TX
⁴University of Kansas Medical Center, Kansas City, KS
⁵National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece
⁶Mayo Clinic, Phoenix, AZ
⁷Mayo Clinic, Rochester, MN
⁸Bristol Myers Squibb, Summit, NJ
⁹Hematology, Translational Medicine, Bristol Myers Squibb, Summit, NJ

12:45 PM

580

A Phase 1/1b Study of Parsaclisib Plus Standard Immunochemotherapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma

Yucai Wang, MD, PhD¹, Han W. Tun, MD², Betsy R. LaPlant, MS¹^*, Rebecca L. King, MD¹^*, Ivana N. Micallef¹^*, Madiha Iqbal, MD², Allison C. Rosenthal, DO³, Stephen M. Ansell, MD, PhD¹, Jose C. Villasboas Bisneto, MD¹, Arushi Khurana, MBBS¹, Gita Thanarajasingam, MD¹, Thomas M. Habermann, MD¹, Javier L. Munoz, MD, MS, MBA⁴, Paul J. Hampel, MD¹, Patrick B. Johnston, MD, PhD¹^*, Thomas E. Witzig, MD¹ and Grzegorz S. Nowakowski, MD¹

¹Mayo Clinic, Rochester, MN
²Mayo Clinic, Jacksonville, FL
³Division of Hematology/Oncology Mayo Clinic, Phoenix, AZ
⁴Mayo Clinic, Phoenix, AZ

1:00 PM

581

Fixed-Duration Epcoritamab + R-CHOP Induces High Complete Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Withhigh-Risk Features: Long-Term Results from the Epcore NHL-2 Trial

Lorenzo Falchi, MD¹, Fritz Offner, MD, PhD², Sven de Vos, MD, PhD³^*, Joshua Brody, MD⁴^*, Raul Cordoba, MD, PhD⁵, Kim Linton⁶^*, Sylvia Snauwaert, MD, PhD⁷^*, Michael Roost Clausen, MD, PhD⁸^*, Toshihiko Oki, MD, PhD⁹^*, Andrew J. Steele, PhD¹⁰^*, Yi Hao, DrPH¹⁰^*, Kimberly G. Archer¹⁰^*, Ali Rana, MD, PhD¹⁰^* and David Belada, MD, PhD¹¹

¹Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY
²Universitair Ziekenhuis Ghent, Ghent, Belgium
³Ronald Reagan University of California Los Angeles Medical Center, Los Angeles, CA
⁴Icahn School of Medicine at Mount Sinai, New York, NY
⁵Health Research Institute IIS-FJD, Fundacion Jimenez Diaz University Hospital, Madrid, Spain
⁶The Christie NHS Foundation Trust, Manchester Cancer Research Centre, and Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom
⁷Department of Hematology, AZ Sint-Jan Hospital, Bruges, Belgium
⁸Vejle Hospital, Vejle, Denmark
⁹AbbVie, North Chicago, IL
¹⁰Genmab, Plainsboro, NJ
¹¹4th Department of Internal Medicine – Hematology, University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic

1:15 PM

582

A Randomized Phase 2, Investigator-Led Trial of Glofitamab-R-CHOP or Glofitamab-Polatuzumab Vedotin-R-CHP (COALITION) in Younger Patients with High Burden, High-Risk Large B-Cell Lymphoma Demonstrates Safety, Uncompromised Chemotherapy Intensity, a High Rate of Durable Remissions, and Unique FDG-PET Response Characteristics

Adrian Minson, MBBS^1,2, Emma Verner, MBBS³^*, Pratyush Giri, MBBS⁴^*, Jason Butler, MBBS⁵^*, Wojt Janowski, MD⁶^*, Chan Y. Cheah, MBBS, DMSc⁷^*, Sumita Ratnasingam, MBBS⁸, Shu Min Wong, MBBS⁹^*, Matthew Ku, MBBS, PhD¹⁰^*, Mark S. Hertzberg, MBBS¹¹, Kirsten Herbert, MBBS, PhD¹²^*, Nada Hamad, MBBS, MSc, BSc¹³, Costas K. Yannakou, MBBS, PhD¹⁴^*, Fiona Swain¹⁵^*, Paul Neeson, PhD¹⁶^*, Thiago M. Steiner, PhD¹⁶^*, Javad Saghebi, MBBS¹⁶^*, Piers Blombery, MBBS^1,17, Molly Robertson, RN¹⁶^*, Lei Shong Lau, PhD¹⁶^*, Jing Xie, PhD¹⁶^*, Rory Bennett, MBChB²^*, John F. Seymour, MBBS, PhD^1,18 and Michael J. Dickinson, MBBS, DMedSci^1,2

¹Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC, Australia
²Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, VIC, Australia
³Concord Repatriation General Hospital, Concord, NSW, Australia
⁴Royal Adelaide Hospital, Adelaide, Australia
⁵Department of Haematology and Bone Marrow Transplant, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia
⁶Calvary Mater Newcastle, Newcastle, NSW, Australia
⁷Sir Charles Gairdner Hospital and the University of Western Australia, Nedlands, Australia
⁸University Hospital, Geelong, Australia
⁹Alfred Hospital, Melbourne, Australia
¹⁰St Vincent’s Hospital, Melbourne, VIC, Australia
¹¹Prince of Wales Hospital, Sydney, NSW, Australia
¹²Cabrini Health, Melbourne, VIC, Australia
¹³St Vincent's Hospital, Sydney, NSW, Australia
¹⁴Molecular Oncology and Cancer Immunology, Epworth HealthCare, Melbourne, VIC, Australia
¹⁵Department of Haematology, Princess Alexandra Hospital, Woolloongabba, Australia
¹⁶Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
¹⁷Peter Maccallum Cancer Centre, East Melbourne, VIC, Australia
¹⁸Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

627.O1.6 627. Aggressive Lymphomas: Pharmacologic Therapies: New R-CHOP Combinations for Treatment Naïve DLBCL